Drug Repurposing : An Alternative Strategy to Treat COVID-19
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
In order to curve the ongoing trend of the COVID-19 pandemic and save more lives, effective treatments against COVID-19 are urgently needed. Compared to developing new drugs, which may take too much time, it's more efficient and cost-effective to repurpose existing drugs in the treatment of COVID-19. Fortunately, some of the shared features of COVID-19 and other wellknown diseases make it possible to use old strategies to combat this new challenge. In this paper, we reviewed various possible strategies of drug repurposing in the treatment of COVID-19 and explored the possible scientific mechanisms behind each strategy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Current pharmaceutical biotechnology - 23(2022), 6 vom: 20., Seite 818-827 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han, Pengyu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-viral agents |
|---|
| Anmerkungen: |
Date Completed 15.03.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1389201022666210709141320 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327966920 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327966920 | ||
| 003 | DE-627 | ||
| 005 | 20231225201945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389201022666210709141320 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM327966920 | ||
| 035 | |a (NLM)34250872 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Han, Pengyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug Repurposing |b An Alternative Strategy to Treat COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a In order to curve the ongoing trend of the COVID-19 pandemic and save more lives, effective treatments against COVID-19 are urgently needed. Compared to developing new drugs, which may take too much time, it's more efficient and cost-effective to repurpose existing drugs in the treatment of COVID-19. Fortunately, some of the shared features of COVID-19 and other wellknown diseases make it possible to use old strategies to combat this new challenge. In this paper, we reviewed various possible strategies of drug repurposing in the treatment of COVID-19 and explored the possible scientific mechanisms behind each strategy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anti-viral agents | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immuno-regulation | |
| 650 | 4 | |a Risk factor | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Surfactants | |
| 650 | 4 | |a pH | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Zheng, Huifang |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Pingping |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Geng, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Dianxing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical biotechnology |d 2000 |g 23(2022), 6 vom: 20., Seite 818-827 |w (DE-627)NLM11369072X |x 1873-4316 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2022 |g number:6 |g day:20 |g pages:818-827 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389201022666210709141320 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2022 |e 6 |b 20 |h 818-827 | ||